The Use of Phospholipids to Make Pharmaceutical Form Line Extensions

Abstract

This review describes the use of phospholipid excipients to make Pharmaceutical Form (Dosage Form) Line Extensions of existing drugs as part of a Product Life Cycle Management. Product examples and development candidates, which show the versatility of phospholipids as key excipients in formulations to develop line extension drug products for any administration route by reformulating existing products, are provided. The resulting patented products enable the application of a drug substance for another administration route or show an increased efficacy and/or reduced toxicity of the formulated drug substances, or enable a more convenient use, through reduction of dosing frequency, or adapt a product for regulatory requirements for specific patient populations. Parenteral line extensions for lipophilic drugs using non‐toxic phospholipid‐based solubilising formulations are clearly an alternative to products with solubilising synthetic detergents with the risk for allergic and anaphylactic reactions. This review draws the attention to academic and industrial formulation scientist to consider using phospholipid excipients to reformulate existing products to improve the product properties by an active product life cycle management. Phospholipids are suitable for this purpose because they are biocompatible, biodegradable, non‐toxic, and available at large scale and of pharmaceutical grade. Besides, they are well known to regulatory authorities.

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments

“…Moreover, due to the structure, we get targeted therapy as it penetrates the imperfect vessels produced by tumors, and the addition of polyethylene glycols on the surface may increase the time that cisplatin stays in the human bloodstream. Preclinical studies of lipoplatin revealed less nephrotoxicity than cisplatin [ 82 , 83 ].…”

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

“…Based on the findings from our screen and subsequent analyses indicating ratiometric drug synergy between MRX-2843 and vincristine, we developed multiagent lipid nanoparticles closely related in lipid composition to FDA-approved products such as AmBisome and Vyxeos, both of which are comprised of phosphatidylcholine, phosphatidylglycerol, and cholesterol [55]. To further enhance the feasibility of clinical-scale manufacturing, we also devised a method to co-load defined ratios of MRX-2843 and vincristine using a gradient-based method which is notable in its typically high encapsulation efficiency, scalability, and reproducibility, as well as its utilization to manufacture FDA-approved products, Onivyde and Doxil [56, 57].…”

Buprenorphine X-waiver exemption – beyond the basics for the obstetrical provider

“…Brixadi® is currently being used in the NIDA-funded Clinical Trials Network's multi-center randomized controlled trial Medication treatment for Opioid use disorder in expectant Mother (MOMs), comparing sublingual and long-acting buprenorphine during pregnancy and one year postpartum 68 . Brixadi® product does not use NMP as part of the delivery device 69 . Long-acting buprenorphine has limited but increasing data in pregnancy suggesting its safety and efficacy in the postpartum population, therefore, the postpartum period may be an ideal time to transition 11,70,71 .…”